Table 2:

Treatment-emergent adverse events

	Part A: schedule 1 (n=6)				Part A: schedule 2 (n=6)				Part A: schedule 3 (n=6)				Part B (n=25)				Overall study cohort (n=43)
	Grade 1–2	Grade 3	Grade 4	Grade 5	Grade 1–2	Grade 3	Grade 4	Grade 5	Grade 1–2	Grade 3	Grade 4	Grade 5	Grade 1–2	Grade 3	Grade 4	Grade 5	Grade 1–2	Grade 3	Grade 4	Grade 5
Fatigue	1 (17%)	0	0	0	1 (17%)	0	0	0	4 (67%)	0	0	0	20 (80%)	0	0	0	26 (60%)	0	0	0
Nausea	2 (33%)	0	0	0	2 (33%)	0	0	0	4 (67%)	0	0	0	9 (36%)	0	0	0	17 (40%)	0	0	0
Joint pain or arthritis	2 (33%)	0	0	0	1 (17%)	1 (17)	0	0	1 (17%)	0	0	0	9 (36%)	0	0	0	13 (30%)	1 (2%)	0	0
Decreased appetite	2 (33%)	0	0	0	2 (33%)	0	0	0	3 (50%)	0	0	0	3 (12%)	0	0	0	10 (23%)	0	0	0
Xerostomia	2 (33%)	0	0	0	1 (17%)	0	0	0	1 (17%)	0	0	0	6 (24%)	0	0	0	9 (21%)	0	0	0
Diarrhoea	0	0	0	0	2 (33%)	0	0	0	2 (33%)	0	0	0	5 (20%)	0	0	0	7 (16%)	0	0	0
Hypothyroidism	1 (17%)	0	0	0	0	0	0	0	0	0	0	0	5 (20%)	0	0	0	6 (14%)	0	0	0
Rash	1 (17%)	0	0	0	0	0	0	0	0	0	0	0	1 (4%)	0	0	0	3 (7%)	0	0	0
Pruritus	0	0	0	0	1 (17%)	0	0	0	1 (17%)	0	0	0	1 (4%)	0	0	0	3 (7%)	0	0	0
Dry eyes	0	0	0	0	0	0	0	0	0	0	0	0	3 (12%)	0	0	0	3 (7%)	0	0	0
Vomiting	0	0	0	0	1 (17%)	0	0	0	0	0	0	0	1 (4)	0	0	0	2 (5%)	0	0	0
Pneumonitis	0	0	0	0	0	0	0	0	0	1 (17%)	0	0	1 (4%)	0	0	0	1 (2%)	1 (2%)	0	0
Thrombocytopenia	1 (17%)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1 (2%)	0	0	0
Anaemia	0	0	0	0	1 (17%)	0	0	0	0	0	0	0	0	0	0	0	1 (2%)	0	0	0
Neutropenia	0	0	0	0	1 (17%)	0	0	0	0	0	0	0	0	0	0	0	1 (2%)	0	0	0

Data are n (%).